Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02338973

Enrollment

Registered

2015-01-15

Start date

2015-01-14

Completion date

2018-07-26

Last updated

2019-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Ophthalmic Diseases, Inherited Retinal Degeneration

Keywords

Macular Edema, Rod-Cone Dystrophy, Inherited Retinal Degeneration, Enhanced S-Cone Syndrome, Interferon Gamma

Brief summary

Background: \- People with rod-cone dystrophy (RCD) or enhanced S-cone syndrome (ESCS) have excess fluid under the retina of their eye. This can cause vision loss. The medicine interferon gamma-1b may help people with these diseases. Objectives: \- To see if interferon gamma-1b eyedrops are safe for people with RCD or ESCS. To see if the medicine can decrease retina fluid and help prevent vision loss. Eligibility: \- People at least 12 years old with RCD or ESCS. Those with ESCS must have two mutations in the NR2E3 gene. Design: * Participants will be screened with medical history, physical exam, eye exam, and blood tests. * Participants will stay at NIH for 3 days and get the first eyedrops. * Participants will give themselves 4 study eyedrops 4 times daily for 2 weeks and keep a diary. * Participants will have 5 outpatient visits over 8 weeks, 2 of which are telephone assessments. They may have: * Repeats of screening tests. * Questionnaires. * Small piece of skin removed. * Eye exams, including eye dilation and tasks on computer screens. * Fluorescein angiography. A dye injected into an arm vein will travel to the blood vessels in the eyes. A camera will take pictures. * Electroretinography. Participants will sit in the dark wearing eyepatches. A small electrode will be taped to the forehead. After 30 minutes, researchers will remove the eyepatches and put in numbing eyedrops and contact lenses. Participants will watch flashing lights. * Electrooculography. Electrodes will be attached outside of the eyes and eye function will be measured in the dark and the light. * Participants will have a follow-up visit after 52 weeks.

Detailed description

Objective: Rod-cone dystrophy (RCD) is a term applied to a number of genetically heterogenous diseases presenting with night vision abnormalities, visual field defects and reduced rod electroretinography responses. Enhanced S-Cone syndrome (ESCS) is a rare autosomal recessive retinal disease with a developmental and a degenerative aspect. Macular cystic changes, often florid and usually resulting in a reduction of central acuity, are frequently associated with both diseases. The reason for this association is not well understood. Acetazolamide (Diamox) and Dorzolamide (Trusopt) have been reported to have variable success in reducing these cystic changes but the effect is frequently inadequate. The objective of this study is to evaluate the safety and potential efficacy of Interferon (IFN) gamma-1b administered topically for macular edema/retinal schisis cysts in RCD and ESCS. Possible disease-related pathophysiologic mechanisms will be explored using induced pluripotent stem cell (iPSC) protocols leading to iPSC-derived retinal pigment epithelium (RPE) and photoreceptor generation. Study Population: Up to five participants with RCD with significant macular cystic changes and up to five participants with ESCS with significant macular cystic changes will be enrolled to receive IFN gamma-1b administered topically in one eye. However, up to an additional two participants may be enrolled in order to obtain the five participants in each disease group to be included in the primary analysis if any participants withdraw from the study prior to receiving five days of treatment. Design: This is a single-center, prospective, uncontrolled, unmasked pilot Phase I/II study of the safety, tolerability and possible efficacy of IFN gamma-1b in participants with RCD and ESCS and macular cystic changes. One eye of up to five participants with RCD with significant macular cystic changes and up to five participants with ESCS with significant macular cystic changes \[evidenced by optical coherence tomography (OCT) \>275 microns central macular thickness and/or disruption of foveal contour\] will receive topical IFN gamma-1b instilled as drops on the cornea. The initial stage of the study will include two participants from each disease category. Once all four participants have completed the 8-week visit, enrollment will be halted. Safety Adverse Event Review Committee members unaffiliated with the study will review the data as a preliminary assessment of safety and efficacy and to determine whether enrollment should continue. If the committee determines enrollment will continue, three additional participants with RCD and three participants with ESCS will be enrolled. The study will be completed once the final participant has received one year of follow-up. Outcome Measures: The primary outcome measure related to the safety and tolerability of IFN gamma-1b administered topically at the prescribed dosage for macular cystic changes in participants with RCD and ESCS will be assessed by the number and severity of adverse events related to the IP and the number of withdrawals at 52 weeks (one year) post-administration. Additional safety of IFN gamma-1b administered topically in participants with RCD and ESCS will be determined from the assessment of retinal function, ocular structure and occurrence of adverse events at all time points. Secondary outcomes include changes in visual function including visual acuity and microperimetry, and retinal imaging with OCT and fluorescein angiography.

Interventions

DRUGInterferon gamma-1b

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: To be eligible, the following inclusion criteria must be met, where applicable. 1. Participant must be 12 years of age or older. 2. Participant (or legal guardian or legal representative) must understand and sign the protocol informed consent. 3. Participant is willing to comply with the study procedures and is expected to be able to return for all study visits. 4. Participant must carry a clinical diagnosis of RCD or ESCS. 5. ESCS participant must have molecular confirmation with two alleles for NR2E3 gene mutations 6. Female participant of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must be willing to undergo pregnancy tests at scheduled study visits. 7. Female participant of childbearing potential, and any male participant able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two reliable methods of contraception while taking the IP and six weeks after completion. Acceptable methods of contraception include: * Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring); * Intrauterine device; * Barrier methods (diaphragm, condom) with spermicide; or * Surgical sterilization (tubal ligation).

Exclusion criteria

A participant is not eligible if any of the following

Design outcomes

Primary

Measure	Time frame	Description
Number and Severity of IP-related AEs	Study duration, up to 52 weeks	The number and severity of adverse events related to the investigation product (IP).
Number of Participants Who Withdrew	Study duration, up to 52 weeks	The number of participants who withdrew early.

Secondary

Measure	Time frame	Description
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Day 3	Change in BCVA from baseline as compared to Day 3 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Week 2	Change in BCVA from baseline as compared to Week 2 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Week 5	Change in BCVA from baseline as compared to Week 5 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Week 8	Change in BCVA from baseline as compared to Week 8 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Week 52	Change in BCVA from baseline as compared to Week 52 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Day 1	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Day 2	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Day 3	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Week 2	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Week 5	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Week 8	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.
Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Week 52	Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Day 1	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Day 1	Change in BCVA from baseline as compared to Day 1 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Day 3	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Week 2	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Week 5	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Week 8	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Week 52	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Day 1	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Day 2	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Day 3	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Week 2	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Week 5	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Week 8	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Week 52	Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.
Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.	Day 2 and Week 5	Change in central visual field sensitivity as measured by microperimetry testing at Day 2 and Week 5 compared to baseline in both study and fellow eyes.
Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Day 2	Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.
Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Day 2	Change in BCVA from baseline as compared to Day 2 by participant in both study and fellow eyes.

Countries

United States

Participant flow

Pre-assignment details

People with rod-cone dystrophy (RCD) and enhanced S-cone syndrome (ESCS) were combined as pre-specified in the study protocol

Participants by arm

Arm	Count
Interferon Gamma-1b Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks Interferon gamma-1b	4
Total	4

Baseline characteristics

Characteristic	Interferon Gamma-1b
Age, Categorical <=18 years	1 Participants
Age, Categorical >=65 years	1 Participants
Age, Categorical Between 18 and 65 years	2 Participants
Age, Continuous	45.8 years
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants
Race (NIH/OMB) Asian	0 Participants
Race (NIH/OMB) Black or African American	1 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	2 Participants
Sex: Female, Male Female	2 Participants
Sex: Female, Male Male	2 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 4
other Total, other adverse events	2 / 4
serious Total, serious adverse events	1 / 4

Outcome results

Primary

Number and Severity of IP-related AEs

The number and severity of adverse events related to the investigation product (IP).

Time frame: Study duration, up to 52 weeks

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Number and Severity of IP-related AEs	Severity: Mild	3 adverse events related to IP
Interferon Gamma-1b	Number and Severity of IP-related AEs	Severity: Severe	1 adverse events related to IP

Primary

Number of Participants Who Withdrew

The number of participants who withdrew early.

Time frame: Study duration, up to 52 weeks

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Interferon Gamma-1b	Number of Participants Who Withdrew	0 Participants

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1

Change in BCVA from baseline as compared to Day 1 by participant in both study and fellow eyes.

Time frame: Day 1

Population: BCVA values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	39 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	14 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	18 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	74 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	32 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	76 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	79 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	44 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	62 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	70 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	5 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	4 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	-7 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	-1 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 002	1 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 003	-6 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 004	2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1	Participant 001	-1 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2

Change in BCVA from baseline as compared to Day 2 by participant in both study and fellow eyes.

Time frame: Day 2

Population: BCVA values are presented for Baseline and Day 2 and the change at Day 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	14 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	39 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	75 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	36 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	75 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	21 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	58 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	81 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	69 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	45 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	7 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	6 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	-2 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	-3 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 001	1 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 003	-7 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 004	3 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2	Participant 002	-3 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3

Change in BCVA from baseline as compared to Day 3 by participant in both study and fellow eyes.

Time frame: Day 3

Population: BCVA values are presented for Baseline and Day 3 and the change at Day 3 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	39 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	14 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	41 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	81 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	23 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	74 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	61 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	78 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	47 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	73 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	9 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	4 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	5 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 002	0 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 001	-2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 003	-3 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3	Participant 004	5 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2

Change in BCVA from baseline as compared to Week 2 by participant in both study and fellow eyes.

Time frame: Week 2

Population: BCVA values are presented for Baseline and Week 2 and the change at Week 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	39 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	14 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	23 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	66 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	0 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	75 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	78 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	42 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	66 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	67 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	-3 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	9 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	-39 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	-2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 002	5 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 003	-9 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 004	0 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2	Participant 001	-2 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5

Change in BCVA from baseline as compared to Week 5 by participant in both study and fellow eyes.

Time frame: Week 5

Population: BCVA values are presented for Baseline and Week 5 and the change at Week 5 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	39 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	14 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	26 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	72 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	0 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	71 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	82 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	45 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	65 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	75 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	3 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	12 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	-39 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	-6 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 002	4 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 003	-1 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 004	3 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5	Participant 001	2 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52

Change in BCVA from baseline as compared to Week 52 by participant in both study and fellow eyes.

Time frame: Week 52

Population: BCVA values are presented for Baseline and Week 52 and the change at Week 52 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	14 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	39 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	42 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	76 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	20 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	79 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	47 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	65 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	44 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	78 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	65 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	65 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	8 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	2 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	-4 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	6 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 004	2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 001	-2 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 003	-11 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52	Participant 002	4 letters read

Secondary

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8

Change in BCVA from baseline as compared to Week 8 by participant in both study and fellow eyes.

Time frame: Week 8

Population: BCVA values are presented for Baseline and Week 8 and the change at Week 8 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	77 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	39 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	69 letters read
Interferon Gamma-1b	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	14 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	76 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	80 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	61 letters read
BCVA at Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	42 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	24 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	43 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	74 letters read
BCVA at Day 1 in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	72 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	47 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	70 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	80 letters read
BCVA at Day 1 in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	65 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	4 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	-3 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	10 letters read
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	3 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 003	-6 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 002	4 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 001	0 letters read
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8	Participant 004	5 letters read

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.

Time frame: Day 1

Population: Central Retinal Thickness values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	297.5 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	1393 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	1394.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	598 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	602 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	314 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	270.5 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	232.5 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	298.5 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	713.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	-115 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	1.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	16.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 002	13.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 003	-70.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 004	-9 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1	Participant 001	1.5 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.

Time frame: Day 2

Population: Cirrus OCT values are presented for Baseline and Day 2 and the change at Day 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	297.5 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	1393 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	1392.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	613 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	605 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	309.5 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	279 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	220 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	304.5 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	700.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	-100 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	-0.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	8 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	12 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 002	19.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 003	-83.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 004	-21.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2	Participant 001	10 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.

Time frame: Day 3

Population: Cirrus OCT values are presented for Baseline and Day 3 and the change at Day 3 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	297.5 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	1393 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	1361.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	621 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	587.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	323 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	274 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	220 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	299 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	682.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	-92 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	-31.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	-9.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	25.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 002	14 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 003	-101.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 004	-21.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3	Participant 001	5 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.

Time frame: Week 2

Population: Cirrus OCT values are presented for Baseline and Week 2 and the change at Week 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	1393 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	297.5 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	534 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	330 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	517 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	1193 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	300 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	700 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	267 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	208 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	-196 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	-63 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	32.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	-200 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 002	15 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 003	-84 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 004	-33.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2	Participant 001	-2 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.

Time frame: Week 5

Population: Cirrus OCT values are presented for Baseline and Week 5 and the change at Week 5 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	297.5 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	1393 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	1083 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	473 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	605 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	374 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	276 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	206 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	302 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	580 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	-240 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	-310 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	8 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	76.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 002	17 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 003	-204 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 004	-35.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5	Participant 001	7 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.

Time frame: Week 52

Population: Cirrus OCT values are presented for Baseline and Week 52 and the change at Week 52 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	1393 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	297.5 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	241.5 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	285 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	1175 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	437 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	503 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	302 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	270 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	197 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	457 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	307 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	-94 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	4.5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	-276 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	-218 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 004	-44.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 001	1 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 002	22 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52	Participant 003	-327 μm

Secondary

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8

Change in central retinal thickness as measured on Cirrus OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.

Time frame: Week 8

Population: Cirrus OCT values are presented for Baseline and Week 8 and the change at Week 8 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	297.5 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	597 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	713 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	1393 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	784 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	285 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	269 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	241.5 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	1000 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	456 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	544 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	353 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	276 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	220 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	224 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	667 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	-257 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	-393 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	-53 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	55.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 002	-61 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 003	-117 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 004	-21.5 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8	Participant 001	7 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.

Time frame: Day 1

Population: Central Retinal Thickness values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	260 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	319 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	607 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	605 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	331 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	1418 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	317 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	258 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	275 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	703 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	-97 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	24 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	5 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	-12 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 002	-2 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 003	-42 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 001	-3 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1	Participant 004	-2 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.

Time frame: Day 2

Population: Central Retinal Thickness values are presented for Baseline and Day 2 and the change at Day 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	1427 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	624 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	611 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	321 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	278 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	246 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	318 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	682 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	-78 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	14 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	-8 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	14 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 002	-1 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 003	-63 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 004	-14 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2	Participant 001	0 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.

Time frame: Day 3

Population: Central Retinal Thickness values are presented for Baseline and Day 3 and the change at Day 3 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	587 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	607 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	1393 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	330 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	277 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	320 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	243 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	656 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	-95 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	-20 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	-32 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	23 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 004	-17 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 003	-89 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 001	-1 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3	Participant 002	1 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.

Time frame: Week 2

Population: Central Retinal Thickness values are presented for Baseline and Week 2 and the change at Week 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	1233 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	552 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	530 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	333 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	276 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	234 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	317 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	687 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	-150 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	-180 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	-89 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	26 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 002	-2 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 003	-58 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 004	-26 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2	Participant 001	-2 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.

Time frame: Week 5

Population: Central Retinal Thickness values are presented for Baseline and Week 5 and the change at Week 5 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	1089 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	509 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	576 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	385 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	282 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	243 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	316 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	591 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	-193 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	-324 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	-43 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	78 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 002	-3 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 003	-154 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 004	-17 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5	Participant 001	4 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.

Time frame: Week 52

Population: Central Retinal Thickness values are presented for Baseline and Week 52 and the change at Week 52 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	1413 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	307 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	1221 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	309 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 002	497 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	445 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	277 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	233 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	472 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	-192 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 002	-122 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	2 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	-257 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 004	-27 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 001	-1 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52	Participant 003	-273 μm

Secondary

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8

Change in central retinal thickness as measured on Spectralis OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.

Time frame: Week 8

Population: Central Retinal Thickness values are presented for Baseline and Week 8 and the change at Week 8 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	307 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	619 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	702 μm
Interferon Gamma-1b	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	1413 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	745 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	319 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	278 μm
BCVA at Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	260 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	1020 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	486 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	545 μm
BCVA at Day 1 in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	370 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	280 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	250 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	313 μm
BCVA at Day 1 in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	657 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	-216 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	-393 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	-74 μm
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	63 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 002	-6 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 003	-88 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 004	-10 μm
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8	Participant 001	2 μm

Secondary

Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.

Change in central visual field sensitivity as measured by microperimetry testing at Day 2 and Week 5 compared to baseline in both study and fellow eyes.

Time frame: Day 2 and Week 5

Arm	Measure	Group	Value (MEAN)	Dispersion
Interferon Gamma-1b	Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.	Day 2 Study Eye	-0.3 dB	Standard Deviation 1.6
Interferon Gamma-1b	Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.	Day 2 Fellow Eye	-1.4 dB	Standard Deviation 0.6
Interferon Gamma-1b	Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.	Week 5 Study Eye	-1.1 dB	Standard Deviation 1.1
Interferon Gamma-1b	Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.	Week 5 Fellow Eye	-1.7 dB	Standard Deviation 1.4

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 1 by participant in both study and fellow eyes.

Time frame: Day 1

Population: Subretinal Fluid Volume values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	36.3 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	7.25 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	14.15 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	9.25 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	11.2 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	13.95 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	37.7 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	15.15 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	7.35 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	11.25 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	7.35 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	17.2 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	9.2 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	1.4 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	-0.95 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	-0.2 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	0.1 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 001	0.25 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 004	-0.05 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 003	-1.35 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1	Participant 002	0.05 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 2 by participant in both study and fellow eyes.

Time frame: Day 2

Population: Subretinal Fluid Volume values are presented for Baseline and Day 2 and the change at Day 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	7.25 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	36.3 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	9.25 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	37.3 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	15.15 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	14.1 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	7.1 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	7 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	9.05 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	10.9 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	15.55 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	-0.95 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	1 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	-0.05 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	-0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 002	-0.3 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 003	-3 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 004	-0.2 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2	Participant 001	-0.1 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 3 by participant in both study and fellow eyes.

Time frame: Day 3

Population: Subretinal Fluid Volume values are presented for Baseline and Day 3 and the change at Day 3 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	36.3 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	7.25 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	9.25 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	18.55 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	7.5 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	13.75 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	15.3 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	35 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	7.45 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	17 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	9.1 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	11.25 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	0.25 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	-0.4 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	-0.8 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	-1.3 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 004	-0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 001	0.35 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 003	-1.55 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3	Participant 002	0.05 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 2 by participant in both study and fellow eyes.

Time frame: Week 2

Population: Subretinal Fluid Volume values are presented for Baseline and Week 2 and the change at Week 2 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	7.25 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	36.3 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	9.25 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	32.5 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	7.6 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	14.3 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	13.1 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	11 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	9 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	7.3 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	17 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	0.35 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	-3.8 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	-1.05 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	-1.8 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 004	-0.25 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 003	-1.55 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 001	0.2 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2	Participant 002	-0.2 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 5 by participant in both study and fellow eyes.

Time frame: Week 5

Population: Subretinal Fluid Volume values are presented for Baseline and Week 5 and the change at Week 5 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	7.25 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	36.3 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	9.25 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	29.1 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	14 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	13.9 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	7.4 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	7.3 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	9.1 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	11.2 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	15.7 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	-2.1 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	-7.2 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	-0.25 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 002	0 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 003	-2.85 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 004	-0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5	Participant 001	0.2 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 52 by participant in both study and fellow eyes.

Time frame: Week 52

Population: Subretinal Fluid Volume values are presented for Baseline and Week 52 and the change at Week 52 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	36.3 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	7.25 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	9.25 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	7.1 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	12.7 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	6.9 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	32.3 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	13.8 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	8.9 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	7 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	11.3 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	14.3 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	-0.35 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	-1.45 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	-2.3 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	-4 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 002	0.1 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 001	-0.1 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 004	-0.35 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52	Participant 003	-4.25 mm^3

Secondary

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8

Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Week 8 by participant in both study and fellow eyes.

Time frame: Week 8

Population: Subretinal Fluid Volume values are presented for Baseline and Week 8 and the change at Week 8 from Baseline for each participant (study and fellow eye).

Arm	Measure	Group	Value (NUMBER)
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	7.25 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	14.15 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	16.1 mm^3
Interferon Gamma-1b	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	36.3 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	18.55 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	11.2 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	7.1 mm^3
BCVA at Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	9.25 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	27.6 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	13.8 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	13.5 mm^3
BCVA at Day 1 in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	7.4 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	7.4 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	9.4 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	10.9 mm^3
BCVA at Day 1 in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	17.1 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	-2.3 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	-8.7 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	-0.65 mm^3
Difference in BCVA at Day 1 From Baseline in Study Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 002	-0.3 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 003	-1.45 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 004	0.15 mm^3
Difference in BCVA at Day 1 From Baseline in Fellow Eye	Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8	Participant 001	0.3 mm^3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Number and Severity of IP-related AEs

Number of Participants Who Withdrew

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52

Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52

Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52

Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8

Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52

Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8